In hepatoma cells, treatment with erastin or sorafenib increases NFE2L2 protein levels in both nuclear and whole cell extracts, as well as NFE2L2 transcriptional activity and NFE2L2 cofactor binding (109). This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.